Sichuan Biokin Pharmaceutical Co.,Ltd.

SHSE:688506 Stock Report

Market Cap: CN¥79.0b

Sichuan Biokin PharmaceuticalLtd Past Earnings Performance

Past criteria checks 4/6

Sichuan Biokin PharmaceuticalLtd has been growing earnings at an average annual rate of 35.7%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 736.5% per year. Sichuan Biokin PharmaceuticalLtd's return on equity is 85.2%, and it has net margins of 74.4%.

Key information

35.7%

Earnings growth rate

34.5%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate736.5%
Return on equity85.2%
Net Margin74.4%
Last Earnings Update31 Mar 2024

Recent past performance updates

Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Earnings May Just Be The Starting Point

May 03
Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Earnings May Just Be The Starting Point

Recent updates

Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Earnings May Just Be The Starting Point

May 03
Sichuan Biokin PharmaceuticalLtd's (SHSE:688506) Earnings May Just Be The Starting Point

Revenue & Expenses Breakdown

How Sichuan Biokin PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:688506 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 245,9014,391364836
31 Dec 23562-780361746
30 Sep 23601-555383601
30 Jun 23710-473420535
31 Mar 23705-404421463
31 Dec 22703-282411375
30 Sep 22663-320396385
31 Dec 21797-100465279
31 Dec 201,01338635196
31 Dec 191,2078827181
31 Dec 14418172240
31 Dec 13415352130

Quality Earnings: 688506 has high quality earnings.

Growing Profit Margin: 688506 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 688506's earnings have grown significantly by 35.7% per year over the past 5 years.

Accelerating Growth: 688506 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 688506 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).


Return on Equity

High ROE: 688506's Return on Equity (85.2%) is considered outstanding.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.